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Immune responses result from different immune cells acting in synergy to successfully fight infections.
This requires a high degree of regulation to prevent excessive production of inflammatory products lead-
ing to other disease forms. Regulatory B cells are classified based on surface immunoglobulin expression.
These cells are reported to resolve inflammation during chronic or autoimmune diseases. However, dur-
ing chronic inflammation, their frequencies have been shown to be affected, and they can be induced
by exposure to extracellular binding immunoglobulin protein (BiP). This review focuses on the effects on
immune cells by extracellular or secreted BiP during various chronic inflammatory responses. For example,
cell stress associated with Mycobacterium tuberculosis infection leads to accumulation of unfolded pro-
teins that subsequently activate BiP and its three signal transducers intracellularly. Furthermore, BiP can
be translocated from the endoplasmic reticulum to the extracellular environment where it binds immune
cells as an autoantigen and leads to functional changes.
Lay abstract: Immune responses during tuberculosis disease require balanced cell interactions. These in-
clude antigen-presenting cells, effector cells and regulatory cells. B lymphocytes can mediate regulatory
function during chronic diseases and lead to better disease outcome. These specialized cells mediate this
function through both surface and soluble protein expression. Their development can be facilitated by
different stimuli including binding immunoglobulin protein. This protein resides in the endoplasmic retic-
ulum where it functions in proper protein folding; however, it can escape this location to the extracellular
phase, where it affects immune cell function leading to development of regulatory traits on B cells.
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Immunological studies have shown that successful clearance of any invading pathogen depends on effective balance
between immune cells and their secreted products such as cytokines, antibodies and chemokines. Depending on the
nature of infection, immune cell balance can be altered through biological processes such as necrosis, pyroptosis,
programmed cell death and apoptosis [1]. These cellular processes are triggered mostly by intracellular pathogens
such as Mycobacterium tuberculosis, which has evolved to suppress immune responses by effector T cells through
release of bacterial vesicles that expresses lipoarabinomannan and other lipoglycans [2]. These bacteria suppress
immune activation through recruitment of mesenchymal stem cells, which secrete immunosuppressive cytokines
and nitric oxide [3].
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Figure 1. Different B cell functional
response to inflammation.
Stimulation of any of the B cell
functions depend on the nature of
the pathogenic material, whereas
memory B cells are long lasting
immunological memory cells that
bear specific receptors from previous
infection.
Even though the Bacillus Calmette-Guerin (BCG) vaccination has been in use for years as it stimulates the
immune system and shortens the specific antibody response against M. tuberculosis infection, which targets lipoara-
binomannan embedded on their cell wall [4], there is still a need for advances that will better eradiate or control the
infection. These antibodies are secreted by a subpopulation of B cells (plasma cells). Furthermore, they facilitate
rapid cell-mediated immunity through pathogen opsonization and binding of their Fcγ receptors (FcγR) with
professional antigen-presenting cells (APC) that result in internalization of the pathogen [5]. However, M. tuber-
culosis is known to reside and multiply within these antigen-presenting cells, leading to formation of granuloma
structures [6,7]. Dissemination of these structures and progression to active tuberculosis has been shown to affect
the frequency of immunological cells such as circulating peripheral B cells [8,9]. The tuberculosis (TB) pathogen
takes advantage of this imbalance in the immune system and multiplies further, thus infecting more and more cells.
Immune system inadequacy or manipulation by M. tuberculosis has highlighted the importance of exploring other
functions played by immune cell subtypes as a means to better control infection. It has become evident through
research that regulatory functions in different immunological cells, including B cells, play more than just a role
of suppressing aggressive immune responses during autoimmune and infectious diseases. These regulatory subsets
play a major role in balancing the immune system and better facilitate elimination and control of pathogens and
resolution of inflammation [10–13]. Immune suppression functions are mediated by a group of specialized regulatory
cells in the innate (myeloid-derived suppressor cells and natural killer cells) [14,15] and adaptive arms, mainly of
the T (regulatory T cells [Tregs]) and B lymphocytes (regulatory B-lymphocytes [Bregs]) [10,16], which express
differential surface receptors and secrete a range of cytokine profiles.
Development of Bregs and other B cell subtypes with different immune function (Figure 1) is enhanced by
various factors including activated/stimulated cellular pathway, type of stimulant and extracellular concentration
of micronutrients [11]. In particular, regulatory function in B cells was first described in experimental autoimmune
encephalomyelitis [17]. It was initially thought that the primary function of these Bregs was to maintain the immune
environment until Tregs are matured enough to take over the role, as the functions mediated by these cell types
(as described by [18]) show them to be alternating, with Bregs regulating early inflammation during experimental
autoimmune encephalomyelitis while regulatory T cell frequencies increase toward the late phase of inflammation.
As depicted in Figure 1 and Figure 2, these cells exert their effect through secretion of soluble proteins (blocking
specific intracellular pathways) and expression of surface ligand molecules such as Fas-L, FoxP3 and programmed
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PD-1Figure 2. Biological pathways
involved in development of
regulatory B cells by various
extracellular antigens have not yet
been characterized and need further
investigations.
death ligand [10,18], which enhance interaction with cells bearing receptors for those specific ligands and induce
apoptosis or programmed death.
Regulatory B cells have been implicated in many inflammatory studies including allograft tolerance, cancer,
autoimmune diseases and infection [9,19,20], where they have been shown to inhibit function and proliferation of
T helper 1 and T helper 17 cells [21–23]. During autoimmune diseases, these cells increase tolerance of selfantigens,
thus preventing destruction of the body’s own cells. Similarly, during infection and inflammatory responses, they
limit aggressiveness of the immune system and prevent persisting immune responses after clearance of the pathogen.
Even though Bregs have not been extensively studied during TB disease, current evidence suggests that B cells with
anti-inflammatory properties are present in smaller numbers in the peripheral stream and these decrease drastically
during chronic infectious diseases [23–25]. These cells are displayed at higher frequencies in healthy individuals and
disappear over time during chronic immune responses, thus leading to immune system imbalance [8,20,25]. Bregs
are continuously reported to be dysfunctional during inflammation; furthermore, this is thought to be associated
with exacerbation of disease state, especially in autoimmune diseases [26].
Various antigens are known to drive development of Bregs through upregulation of IL-10 secretion. These include
BiP, BCG, LPS, infectious agents and TLR-9a [27–29]. In particular, BiP has been shown to resolve inflammation
in rheumatoid arthritis by upregulating anti-inflammatory cytokine production by immune cells [30,31]. However,
as depicted in Figure 2, the biological pathways involved in the development of these cells by different antigens
including BiP remains unknown.
Additionally, functional and phenotypic characterization of these cells is still expanding in the context of
different inflammatory conditions and new makers are still being identified that relate to extracellular environment
composition during their development. It has been shown by recent studies that apart from IL-10 secretion, these
cells are capable of secreting other soluble molecules including sFas-L, TGF-b, granzyme-B and IL-35, which play
crucial roles in suppressing inflammation [10,29,32].
Phenotypically identified subsets of regulatory B cells during inflammation
Identification of Bregs is based on both extracellular surface immunoglobulin expression and cytokine profiles,
merely because these properties determine the mode of regulation by these cell types. As postulated in Figure 3
there are four common categories of Bregs and these include IL-10-producing Bregs (commonly known as B10
cells) that produce IL-10 as major cytokine [33], transforming growth factor-β-producing B cells (B-TGF-β) and
FoxP3-expressing B cells (B-FoxP3) [10]. Additionally, IL-35 is another cytokine secreted by regulatory B cells, either
alone or in conjunction with IL-10, to modulate immune responses during inflammation [34]. Several phenotypes
have been identified based on extracellular surface immunoglobulin expression within each Bregs category in various
studies of both humans and mice.
In humans, the majority of B10 cells are represented by expression of CD19+CD24hiCD38hi,
CD1dhiCD5+, CD19+TIM1+ on their surface [9,23,33,35]. Similarly, Shen et al., (2014) described
a subpopulation of IL-35-producing Bregs differentiating from plasma cells expressing the phenotype
IgM+CD138hiTACI+CRCX+CD1d+Tim1int in mice [34]. However, IL-21 has been shown to drive regulatory
function in B cells by upregulating expression of granzyme-B in conjunction with IL-10. This subset has been
phenotypically identified as CD19+CD38+CD147+CD1d+IgM+ [36]. Contradicting results in relation to IL-10
were observed in an HIV study whereby GraB+ Bregs did not produce IL-10 [36,37]. B cell regulatory function
linked with FasL and PD-L1 expression has been described in both inflammatory and healthy state in humans;
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Figure 3. Circulating CD19+ B cells
have the potential to develop to
regulatory B cells with different
regulatory markers depending on
their stage of development. The
regulatory trait has been identified
within B1 cells, marginal zone B cells
and transitional-2 marginal zone B
cells.
these appear in varying frequencies in relation to the inflammatory state and were reported to be higher in healthy
than in infected individuals [25,29]. CD19+FasL+ and CD19+PD-L1+ regulatory subsets secrete IL-10, although
IL-10 biosynthesis intracellular pathways are not fully exploited by these B cell subpopulations [25,38].
However, there has been reports that a significant amount of IL-10 production by B cells occurs through involve-
ment of toll-like receptor (TLR) molecules rather than B cell receptors or CD40 involvement [39]. CD1dhiCD5+
B cells were reported to be inducible for IL-10 secretion in significant amounts through TLR-9 using LPS and
intracellularly mediated by MyD88/STAT3 pathway [13,33,39]. FoxP3-expressing B cells in healthy human blood
samples were first described in a study by Noh et al., (2010) within the CD19+CD5+ population [40]. These cells
appeared in higher frequencies within the CD5+ group than in the CD5- group, and they also showed increased
apoptotic characteristics than other B cell groups. A subsequent study by Guo et al., (2015) described FoxP3-
expressing CD19+ B cells to be of greater frequencies in healthy individuals than in patients with rheumatoid
arthritis (RA) [10].
Although further studies still need to be done on FoxP3+ B cells, Guo et al., (2015) also compared their frequency
with TGF-β CD19+ B cells and found no significant difference among the expression frequencies of these groups
in both healthy and RA groups [10]. Regulatory function and frequency in B cells and other immune cells is affected
by varying antigens in the cellular environment.
BiP affects immune cell function
The BiP is a 78 kDa heat shock protein naturally occurring in the lumen of the endoplasmic reticulum (ER) and aids
in proper peptide folding [41]. Synthesis and expression of this protein has been reported to be upregulated during
cellular stress that might be due to glucose starvation or in response to accumulation of unfolded proteins within
the cell [42,43]. Its activation/synthesis was initially observed in a study by Munro and Pelham, (1986) where BiP
was shown to be expressed in high concentrations in antibody-producing B cells due to high levels of synthesized
immunoglobulin inhabiting endoplasmic reticulum than in resting/naive B cells [44]. Gass et al., (2002) exploited
the unfolded protein response (UPR) in B lymphocytes and found it to be induced during B cell transition to
antibody secreting plasma cells, thus suggesting a link between upregulation of this protein with immunoglobulin
synthesis [45]. Loss of BiP function in B cells has been associated with inability to secrete functional antibodies,
which may ultimately affect opsonization of invading pathogens [46].
In particular, M. tuberculosis infection exerts stress on immune cells through secretion of ESAT-6, which affects
homeostasis of calcium ions and increases unfolded protein burden in cells due to a metabolic shift. However, it
has been implied that extended ER stress can lead to activation of apoptotic pathways in immune cells resulting
in skewed immunological responses [8,47]. As illustrated in Figure 4, ER stress activates and upregulates expression
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Figure 4. Unfolded protein
response mediated by binding
immunoglobulin protein. Activation
of the ER membrane transducers
leads to a cascade of kinase
phosphorylation that either favors
apoptosis through upregulation of
CHOP or JNK activation. Similarly,
cell survival can be favored by
blocking translation and degrading
synthesized mRNA.
ER: Endoplasmic reticulum; UPR:
Unfolded protein response.
of BiP and other ER chaperones to mitigate the conditions affecting cells [42]. These chaperone proteins bind
unfolded and partially folded proteins and direct them for proper folding in the ribosomes [48]. They also act
as coactivators of three ER membrane signal transducers; PERK, IRE1 and ATF6 (Figure 4), which in turn
phosphorylate transcription factors and cytosol kinase involved in translation termination and cytokine synthesis.
These mechanisms either promote cell apoptosis or cell survival.
Even though BiP is natively an intracellular protein, it has been reported to be capable of translocating to and
being expressed on cell membranes attached to peripheral proteins including both transmembrane and external
proteins such as glycosylphosphotidylinositol. Similarly, it can be secreted into the extracellular environment [49]
where it acts as an autoantigen and exerts effects on immune cells through binding with surface receptors [50,51].
Over the last few years, its effect has been exploited in different immune cells including macrophages, dendritic
cells, monocytes, T cells and B cells. The BiP facilitates differentiation of mature dendritic cells to express an
anti-inflammatory phenotype through upregulation of indoleamine-2,3-dioxygenase (IDO) [30] and also stimulates
myeloid cells to express an anti-inflammatory phenotype mostly observed in immature dendritic cells [52]. In a
study by Corrigall et al., (2004) BiP was shown to act on human peripheral blood mononuclear cells to induce
anti-inflammatory responses through upregulation of IL-10 [50]. It also affects the expression of CD86 and HLA-
DR surface expression on monocytes, which causes these APCs to be unable to activate T cells. The BiP also alters
the ability of memory T cells to recall antigens and initiate secondary responses [31].
Immunological effects caused by BiP have ultimately resulted in study in areas relating to cancer, transplantation
and autoimmune studies [31,53]. Contradicting results, however, were observed in Giardia lamblia infection in
murine samples where recombinant BiP extracted from G lamblia (rGlBiP) demonstrated a pro-inflammatory
response through upregulation of CD80, CD86 and MHC II on mature dendritic cells, leading to increased
production of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α [54]. Another study [41] showed that T
cell surface BiP expression can be upregulated by pro-inflammatories such as TNF-α and IL-1β. Additionally, this
upregulation was associated with increased proliferation of synoviocyte cells and progressive pathogenesis of RA
in synoviocytes. This suggested that T cell surface BiP can modulate pro-inflammatory responses in synoviocytes
Interestingly, transfection of the BiP gene into murine and human PBMC samples using a viral vector has been
evaluated as having the same anti-inflammatory effects as stimulating arthritis inflammation with synthesised
proteins in collagen [55]. Supporting evidence of extracellular BiP binding to immune cells was shown in a study
by Tang et al., (2016) where BiP induced the development of regulatory B cells in murine samples and worked in
synergy with CD40 to suppress proliferation of T cells [29].
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Binding of extracellular BiP with immune cells
The BiP is a member of heat-shock proteins (Hsp70) that has been reported to have immune modulatory functions.
Unlike other members of the Hsp70s, which are implicated in induction of pro-inflammatory immune responses,
BiP is reported to mostly facilitate anti-inflammatory responses. As a result, this chaperone has been studied in the
induction of functional changes in immune cells [50,56,57]. Secreted BiP binds to cell receptors as an autoantigen
and causes functional changes. However, pathways involved in these processes are not fully elucidated (Figure 2),
although it has been stated that most of the Hsp70 proteins are secreted through passive secretion. Studies on
RA and cancer that have identified extracellular BiP observed that it is secreted without its anchor, a four amino
acid sequence KDEL, thus suggesting that it is not available as a result of membrane rupture or cell death [50].
In particular, a study in murine collagen induced arthritis revealed an IL-4 dependent effect of BiP on T cell
responses that leads to secretion of anticollagen specific cytokines including IL-5 and IL-10 [53]. Even though BiP
upregulation is beneficial to immune responses as it activates signal transducers that mediate cytokine and antibody
gene expression; similarly, its downregulation has been associated with benefits in cancer suppression that could be
a target of choice in studies such as for B cell lymphoma.
Targeting this chaperone could be a promising approach that will aid in the development of new therapeutic
procedures that will better control inflammation during diseases [30,52]. Less data have been generated on binding of
extracellular BiP onto immune cells since previous studies have focused mainly on monitoring the cytokine profile
in immune cell samples in the presence of BiP rather than assessing binding receptors or pathways involved during
internalization. However, it has been suggested in a study by Becker et al., (2002) that free Hsp70 proteins binds
immune cells, such as B cells, through CD40 in an ATPase-dependent manner [58]. Even though this pathway has
not been fully studied, BiP binding with immune cells such as B cells was also shown by Tang et al., (2016) using
fluorescently labeled BiP in murine model [29]. Binding and internalization of this chaperone protein on B cell
samples induced upregulation of three populations of Bregs with distinct phenotypes (IL-10hi, PDL-1 and FasL),
thus highlighting different regulatory mechanisms [29].
Regulatory function of mature/active regulatory B cells
Initial studies on Bregs implied that these cells were only modulating immune responses until regulatory T cells
were mature enough to take over the function. However, further studies elaborated on immune functions played by
these cells using murine models and have shown that Bregs exert their function mostly through IL-10 [33,35]. Similar
results have been obtained in human models, where both cytokines and cell surface receptors are implicated in the
regulatory roles of these cells [59]. Even though their development depends on various factors, including the type of
stimulant and the presence of micronutrients to drive immunometabolism, these cells have been shown to inhibit
proliferation and function of macrophages, T helper 1 (Th1), and T helper 17 (Th17) cells, while leaving T helper
2 (Th2) function unaffected [22]. In various studies this was confirmed by a decrease in secreted levels of cytokines
such as IFN-γ and IL-17, while IL-4 levels appear to not be affected by presence of regulatory B cells [22,23].
Breg importance lies in their maintaining immune balance after inflammatory responses in order to prevent
autoimmune diseases progression by suppressing persisting T cell responses [60]. Cell-to-cell immunomodulatory
function of Bregs occurs through expression of ligands that target and bind to specific surface receptors expressed
by other immune cells and this binding further enhances apoptotic pathways. Such immunomodulatory ligands
include PDL-1, which targets PD-1 membrane protein on activated T cells and monocytes; FasL, which stimulates
apoptosis of infected macrophages during chronic infections such as TB [25,61,62]; and GITR, which has been shown
to be associated with negatively modulating proliferation of regulatory T cells during RA through binding to the
GITRligand expressed by these cells [12].
Immune responses driven by low or high frequencies of Bregs
In allograft and autoimmune diseases, high frequency of Bregs is associated with preventing progression into
aggressive stages of inflammation. The functions carried by these cell subsets are highly similar to Tregs; however,
these functions are believed to be alternating during inflammation in a sense that Bregs are mostly active during
the onset of inflammation whereas Tregs come to action toward the end of inflammation. This notion has been
supported in a variety of studies where Bregs were isolated in higher frequencies in healthy individuals but eventually
deplete as inflammatory responses progresses [22,35]. The same ‘depletion-reappearing’ trait of these cells has been
observed in studies focusing on different inflammatory responses using both murine and human models [8,22,25,35].
Recently, it has been observed in human samples studying B cell immune responses during M. tuberculosis infection.
Future Sci. OA (2019) 5(3) future science group
Binding immunoglobulin protein to induce killer regulatory B cells Review
Table 1. Defined regulatory B cell population frequencies in healthy human individuals expressing different surface
markers and exhibiting diverse regulatory mechanisms.
Phenotype Species Percentage (%) Mechanism of suppression [Ref.]




























This was believed to play a part in disease progression as their numbers vanished during active TB disease but,
upon treatment, Bregs reappeared to a frequency equivalent to healthy individuals [62]. Expression of regulatory
traits in B cells has been described in varying frequencies depending on B cell development stage, location and
type of inflammation. Highlighted in Table 1 are the recently reported frequencies of different Breg populations
in uninfected or healthy individuals and these range from 0.1% to as high as 12% of the total described B cell
population. However, in vitro these frequency percentages could be stimulated to increase using different stimulants
among which are LPS, TLR-9 agonist and BGC [24,38,59].
Presence of Bregs and high secretion levels of IL-10 from these cells modulates differentiation of certain T cell
subsets expressing CD4+CD25- T cells to Tregs expressing FoxP3, which further mediate regulatory functions
during inflammation [22]. In vitro work has shown that high levels of IL-10 are linked to impaired secretion and
activity of certain pro-inflammatory cytokines such as TNF-α, IL-12, IL1-β and IL-17 [22,23,65,66]; these are required
during early inflammation to initiate and activate adaptive responses by recruiting T- and B cells. However, in
the context of M. tuberculosis infection, engagement of adaptive responses has been speculated to favor TB disease
progression through the formation of granulomas that later become replication sites for the intracellular pathogen,
leading to more cells being infected within the structure as bacterial numbers grow and infected cells rupture
through cellular necrosis and pyroptosis.
Regulatory B cells as agents in therapeutic interventions
Inflammatory responses directed to intracellular pathogens such as M. tuberculosis face challenges in directly
eliminating the pathogen from inside the cell [67]. This phenomenon results as pathogens such as M. tuberculosis
have evolved a way to suppress destruction by proteolytic enzymes inside the phagosomes [68,69]; additionally,
antibodies and cytokines secreted toward this pathogen cannot penetrate cellular membranes to reach it, thus
resulting in established infection and disease progression [70]. Even though formation of granulomatous structures
during TB helps in containing the pathogen and preventing early spread [71], the pathogen may multiply to higher
numbers and progress to active disease [7,71]. Immune cell activity within the granuloma structure and upregulation
of necrotic cytokines and perforins lead to destruction of infected cells by necrosis, which in turn leads to the release of
more pathogens to infect other cells [72,73]. Comparatively, Bregs have been suggested to induce apoptosis of infected
cells by affecting cellular metabolism – which in turn affects homeostasis of calcium – reactive oxygen species and
nitric oxide, thus affecting survival of the intracellular pathogen [72,74]. This prevents presentation of antigens and
activation of effector T cells, thus limiting activation of adaptive immune responses [31,75]. Stimulating development
or maintaining frequency of these regulatory cells can present more benefits in host-directed immunotherapies and
control of intracellular pathogens like M. tuberculosis.
Conclusion & future perspective
Regulatory characteristic induction by BiP in B cells
Little data are currently available on the induction of human regulatory B cells using BiP, indicating that more work
still needs to be done to understand the pathways involved in the development of these cell types. Previous reports
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have shown that BiP has anti-inflammatory properties through induction of regulatory cells and this has been
evaluated in different inflammatory studies with successful results [31,57]. Apart from inducing immune regulatory
functions, its activity in immunoglobulin folding results in better antibody secretion which in turn facilitates better
control of infectious pathogens [76]. Its biological nature gives it an additional advantage by limiting nonspecific
inflammatory responses that may end up causing immuno-pathogenesis. The availability of this molecule in
extracellular circulation and its autoantigen properties facilitate secretion of autoantibodies against it. This also
shows an additional advantage since immune cells will efficiently opsonize and internalize it, resulting in shorter
time required for development of regulatory traits. Induction of these traits in B cells using BiP in a murine model
study and its implication in inducing regulatory traits in T cells in human model studies have paved the way for,
and indicated a high possibility for, Breg induction by this antigen in human settings [29]. More studies must be
conducted in the context of M. tuberculosis infection and BiP behavior.
Executive summary
• Antigen presenting cells (APCs) opsonize and internalize invading M. tuberculosis particles; however, this
pathogen is able to reside and multiply within these cells leading to granulomatous structure formation.
• B cells can differentiate into a variety of subsets, which includes effector B cells, plasma, memory and regulatory
cells.
• During chronic diseases, including tuberculosis, B cells are shown to be dysfunctional in blood circulation and M.
tuberculosis infection takes advantage of this immune imbalance.
• Regulatory functions mediated by B cells was described during experimental autoimmune encephalomyelitis and
shown to resolve disease progression.
• Apart from IL-10 secretion, these cells express surface markers such as sFas-L, PD-L1 and FoxP3.
• There are four groups of regulatory B cells which are grouped based on their mode of action; IL-10 producing B
cells, TGF-β secreting B cells, IL-35 secreting B cells and FoxP3 expressing B cells.
• Regulatory B cells are known to be inducible by various factors such as BiP, BCG, LPS, infectious agents and TLR-9a.
• Binding immunoglobulin protein (BiP) resides in the endoplasmic reticulum and facilitate proper protein folding;
its activity is induced during cellular stress conditions posed onto cells by accumulation of unfolded proteins
among others.
• Its activation results from the unfolded protein response pathway, which is thought to be a survival mechanism
that T cells use during such conditions; however, prolonged cell stress can lead to induction of apoptotic
pathways.
• Unfolded protein response is also mediated by three endoplasmic reticulum membrane-bound transducers (PERK,
IRE1 and ATF6) that act as coactivators during this pathway and their activity determines between cell survival or
cell apoptosis.
• The BiP can escape intracellular environment and act as autoantigen in the extracellular matrix and its effect has
been observed in various cell types including macrophages, dendritic cells, monocytes T and B cells.
• Its presence in the extracellular matrix has been shown to induce regulatory traits on immune cells and further
resolve inflammation.
• Regulatory B cells are known to inhibit proliferation and functions mediated by macrophages, T helper 1 and T
helper 17 cells, while leaving T helper 2 function unaffected.
• High frequencies of regulatory B cells are associated with preventing disease progression.
• Regulatory B cells disappearance during chronic diseases is thought to play part in disease progression
particularly during TB.
• Ability of BiP to modulate immunological responses and drive anti-inflammatory properties has set a promising
research platform in chronic inflammation.
• Its secretion is suggested to be passive in conjunction with newly synthesized proteins as it was isolated in the
extracellular matrix during rheumatoid arthritis without its membrane anchor sequence.
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